Uptake of biosimilars for TNF- α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland

Conclusion Against the background of a finite healthcare budget, this study shows that increasing use of biosimilars can create the financial savings and space to invest in new innovative therapies for the benefit of many patients.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research